



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 233/11, A61K 31/16	A1	(11) International Publication Number: WO 99/29657 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26315 (22) International Filing Date: 9 December 1998 (09.12.98) (30) Priority Data: 60/069,005 10 December 1997 (10.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,005 (CIP) Filed on 10 December 1997 (10.12.97) (71) Applicant (for all designated States except US): NPS PHARMACEUTICALS, INC. [US/US]; Suite 240, 420 Chipeta Way, Salt Lake City, UT 84018-1256 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BALANDRIN, Manuel, F. [US/US]; 9184 South Winter Wren Drive, Sandy, UT 84093 (US). VANWAGENEN, Bradford, C. [US/US]; 3969 South 3250 East, Salt Lake City, Utah 84124 (US). ARTMAN, Linda, D. [US/US]; 2510 East Skyline Drive, Salt Lake City, UT 84108 (US). MUELLER, Alan, L. [US/US]; 2510 East Skyline Drive, Salt Lake City, UT 84108 (US). SMITH,	Daryl [US/US]; 1592 E. Parkridge Drive, Salt Lake City, UT 84121 (US). (74) Agents: SILVERSTEIN, Sheryl, R. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES (57) Abstract Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological disease or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.		